Penn State Health

Penn State Health hospitals now using plasma from recovered patients as possible treatment for COVID-19

17-Apr-2020 8:30 AM EDT, by Penn State Health

Newswise — Penn State Health has enrolled its first COVID-19 patient into an experimental treatment program called convalescent plasma therapy. Access to this treatment is available through an expanded access program led by Mayo Clinic and coordinated by the U.S. Food and Drug Administration (FDA). Patients at both Penn State Health hospitals are being screened for eligibility to receive this experimental treatment.

Convalescent plasma therapy involves giving patients an infusion of plasma – the liquid portion of the blood – from people who have recovered from an infection with SARS-CoV-2, the virus that causes COVID-19.

“Plasma contains antibodies that may help patients being treated for COVID-19 recover,” said Dr. Melissa George, interim chair of pathology at Penn State Health Milton S. Hershey Medical Center. “Those antibodies may give a patient’s immune system a boost until they can develop their own immune response.” 

An expanded access program allows access to certain investigational new drugs or therapies, like convalescent plasma, and is made available outside of clinical trials. The focus is to provide treatment whereas a clinical trial is focused on research and may involve a patient not receiving the treatment being studied. These programs are sometimes necessary when the presence of a disease is classified as life-threatening or severe and there is no current or readily available off-label intervention. Just like a clinical research trial, patient participation is optional and they must provide informed consent.

“Faculty in the Department of Medicine and the staff at the Milton S. Hershey Medical Center are working tirelessly at the frontline to provide the best care possible utilizing the latest advances in therapy for COVID-19 patients that come to our hospital,” said Dr. Thomas Ma, professor and chair of the Department of Medicine at Penn State College of Medicine. “Convalescent plasma therapy gives frontline providers another tool that may potentially aid in the treatment of critically ill COVID-19 patients.”

Dr. Edward Gunther, a professor of medicine at Penn State College of Medicine and a researcher at Penn State Cancer Institute, is overseeing the program and has been working with physicians to identify COVID-19 positive patients who may be eligible to participate. He works closely with Dr. Karen Krok, who oversees the clinical aspects of requesting and delivering convalescent plasma for eligible COVID-19 patients and Dr. Jennifer Kraschnewski who is offering research support to the team. In addition, Penn State University is a member of the National Center for Advancing Translational Sciences’ Trial Innovation Network through the Penn State Clinical and Translational Science Institute and is reviewing investigational research opportunities for the use of convalescent plasma to treat or prevent COVID-19.

“At first we will offer this treatment to patients with severe or life-threatening COVID-19,” Gunther said. “As more patients around the country recover and access to plasma from those who have recovered increases, we hope to expand the treatment to all patients hospitalized with COVID-19.”

Eligible participants must be at least 17 years of age or older with a laboratory-confirmed diagnosis of infection with SARS-CoV-2, the virus that causes COVID-19. Patients hospitalized at the Milton S. Hershey Medical Center and Penn State Health St. Joseph Medical Center will have access to this treatment.

“As part of a university health system, Penn State Health St. Joseph’s connection to Hershey Medical Center allows us to be able to bring treatments like this to the Berks market faster than if we were an independent hospital,” said Dr. Jeffrey Held, vice president for medical affairs at Penn State Health St. Joseph.

The concept of using blood from recovered patients to treat currently ill patients has been around for almost a century. During recent global outbreaks, researchers investigated this approach in the coronaviruses that caused severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Convalescent plasma had positive effects against these coronaviruses as well as against H1N1 influenza, but it was not effective against Ebola, which is a different type of virus.

Two small research studies conducted in China early this year show that convalescent plasma may help patients recover from COVID-19. Some of those patients were also treated with other experimental drugs, like antivirals – making it hard for medical experts to understand the precise effect of convalescent plasma in their recovery. Based on current knowledge, the FDA has not been able to say whether convalescent plasma will be an effective treatment against COVID-19. While plasma transfusions are generally considered safe for most patients, the risks of convalescent plasma in the context of COVID-19 are not known.

Potential donors who have a positive test result for SARS-CoV-2 and have been symptom-free for 14 days can register with the Red Cross. Due to low availability of testing, it may be up to 28 symptom-free days for a sample to be collected in the absence of a confirmed negative test. Penn State Health patients who may be eligible to donate their plasma towards this effort are being contacted by medical and nurse practitioner students from Penn State College of Medicine and Penn State College of Nursing, under the supervision of internal medicine physician Dr. Chris Sciamanna. Students are helping those participants register with the Red Cross. Blood banks around the country are working to put mechanisms in place to test patients who think they may have had COVID-19 and recovered but were never tested. In the meantime, potential donors are asked to fill out a donor form with the Red Cross.

About Penn State Health
Penn State Health is a multi-hospital health system serving patients and communities across 29 counties in central Pennsylvania. The system includes Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital, and Penn State Cancer Institute based in Hershey, Pa.; Penn State Health St. Joseph Medical Center in Reading, Pa.; and more than 2,000 physicians and direct care providers at more than 100 medical office locations. Additionally, the system jointly operates various health care providers, including Penn State Health Rehabilitation Hospital, Hershey Outpatient Surgery Center, Hershey Endoscopy Center, Horizon Home Healthcare and Pennsylvania Psychiatric Institute. In December 2017, Penn State Health partnered with Highmark Health to facilitate creation of a value-based, community care network in the region. Penn State Health shares an integrated strategic plan and operations with Penn State College of Medicine, the University’s medical school.

About Penn State College of Medicine
Located on the campus of Penn State Health Milton S. Hershey Medical Center in Hershey, Pa., Penn State College of Medicine boasts a portfolio of nearly $100 million in funded research. Projects range from development of artificial organs and advanced diagnostics to groundbreaking cancer treatments and understanding the fundamental causes of disease. Enrolling its first students in 1967, the College of Medicine has more than 1,700 students and trainees in medicine, nursing, other health professions and biomedical research in both Hershey and State College, Pa.




Filters close

Showing results

1120 of 3755
Released: 22-Oct-2020 1:00 PM EDT
Do Asymptomatic Kids with COVID-19 Carry Less Virus?
Ann and Robert H. Lurie Children's Hospital of Chicago

New questions are at the forefront as a study published in the Journal of Clinical Microbiology from nine children’s hospitals finds that most asymptomatic children who tested positive for COVID-19 had relatively low levels of the virus compared to symptomatic children. The authors caution that the reason for this finding is unclear and more questions need to be answered. Were the asymptomatic children generally tested later in their disease, and were their viral loads potentially higher closer to the beginning of their infections? If tested early in disease, would asymptomatic children have viral loads as high as symptomatic children? Or do asymptomatic children typically not carry as much virus as children with symptoms? If so, how would lower viral loads impact the risk of transmission? These questions are essential to further clarify the public health impact of pediatric COVID-19.

Released: 22-Oct-2020 11:55 AM EDT
A video posted by a European-based group called World Doctors Alliance falsely claims the novel coronavirus is “a normal flu virus”
Newswise

A video posted by a European-based group called World Doctors Alliance claims the novel coronavirus is “a normal flu virus” and there is no COVID-19 pandemic. Although the video was removed from Youtube, portions of the video are circulating on Facebook. We rate this claim as false. Scientists universally agree that the cuase of this pandemic is a novel coronavirus, SARS-CoV-2, and not a strain of influenza. COVID-19 is deadlier than the seasonal flu. COVID-19 so far has killed more people in the U.S. than the past five flu seasons combined.

Released: 22-Oct-2020 10:55 AM EDT
Black individuals bear heavy burden of COVID-19 mortality, but key geographic disparities in health determinants exist
University of Alabama at Birmingham

A new study published in the Mayo Clinic Proceedings: Innovations, Quality & Outcomes by University of Alabama at Birmingham researchers showed that Black individuals have a disproportionately higher COVID-19 mortality burden across all of the United States, which is driven by a high incidence of COVID-19 infection. They found that there are key geographic differences in the distribution of health determinants and COVID-19 mortality patterns.

access_time Embargo lifts in 2 days
Embargo will expire: 26-Oct-2020 2:00 PM EDT Released to reporters: 22-Oct-2020 9:35 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2020 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 27-Oct-2020 9:00 AM EDT Released to reporters: 22-Oct-2020 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 27-Oct-2020 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: The Medical Minute: The three types of COVID-19 tests
Released: 22-Oct-2020 8:10 AM EDT
The Medical Minute: The three types of COVID-19 tests
Penn State Health

Eight months into the COVID-19 pandemic, questions about testing abound. With COVID-19 cases trending upward, it’s important to understand when individuals should seek getting tested and what type of test they should have.

Released: 22-Oct-2020 8:05 AM EDT
"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT
Newswise

"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT

Newswise:Video Embedded your-guide-to-a-covid-19-vaccine-what-the-public-needs-to-know
VIDEO
Released: 22-Oct-2020 8:05 AM EDT
Your guide to a COVID-19 vaccine: What the public needs to know
Keck Medicine of USC

Edward Jones-Lopez, MD, MS, a Keck Medicine of USC infectious diseases expert and investigator of one of the Operation Warp Speed vaccine clinical trials, answers the questions on everyone’s mind.

Released: 22-Oct-2020 7:00 AM EDT
Study Helps Explain Declines in Death Rates from COVID-19
NYU Langone Health

Fewer New Yorkers are dying from the coronavirus than health experts had anticipated, a new study shows. Regional death rates have dropped from the highs seen at the start of the outbreak, partially due to a shift in the population contracting the disease toward those who are more resilient.


Showing results

1120 of 3755

close
1.18216